Fig. 1 · Structure

Documents & Downloads

Ro 61-8048

Cat. No. A12833 CAS 199666-03-0

Hydroxylase Inhibitor

Ro 61-8048 is a potent and competitive kynurenine 3-hydroxylase inhibitor (Ki = 4.8 nM, IC50 = 37 nM).

In Stock

Publications for Ro 61-8048

1 publication citing this product

  1. Tianxing Ying, .et al. , Cancers (Basel), 2022, Dec 30;15(1):243 PMID: 36612238

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ro 61-8048 is used as a KMO inhibitor. In a cell-free human KMO assay, its reported IC50 was 5.1 μM. An independent SPR experiment in the same paper measured binding to recombinant human KMO with a KD of 1.1 × 10−5 M. These values describe different endpoints under the reported assay conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
KMO Ki 4.8 nM
KMO 37 nM

Ro 61-8048 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Ro 61-8048 from 4 published references. In vitro models include recombinant human KMO immobilized on a CM5 SPR chip; wild-type HEK293 versus HEK293 cells stably overexpressing human KMO.

Ro 61-8048 In Vitro Studies

In TPC-1 thyroid carcinoma cells, 20 nM Ro 61-8048 reduced CCK-8 cell survival in the SERINC2-knockdown condition; the vector-control comparison was nonsignificant. This combination experiment does not establish an apoptosis-specific endpoint or formal synergy. [2]

Cellular effects depend on the experimental context. In HEK293 cells engineered to overexpress human KMO, 20 μM Ro61-8048 during a 24 h, 500 μM 3-hydroxykynurenine challenge reversed the protection associated with KMO overexpression, as assessed by mitochondrial potential, LDH release and caspase-3/7 activity. [3]

Human KMO activity inhibition assay

Biochemical assay · Cell-free human KMO activity assay; NADPH absorbance readout [1]

Ro 61-8048 served as the reference inhibitor in a duplicate human KMO enzyme assay. The reported IC50 was 5.1 μM. This is an assay-specific activity endpoint, not a cellular treatment concentration or a universal potency value.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of human KMO activityIC50 5.1 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 3C caption: 2–10 μM
Exposure duration
1.5 h
Method
Cell-free enzyme reaction at room temperature
Vehicle
DMSO stock; final DMSO fraction for the Ro concentration series is not specified
Reported limits
Blank/control absorbances are explicit in equation 1; their detailed compositions and IC50 uncertainty are not specified. The substrate mixture description does not unambiguously establish final kynurenine/NADPH concentrations; no final concentrations are reconstructed.
Methods and source locations

Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048

Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.

Sections 2.1 and 2.4; equation 1; section 3.2; Figure 3C; Table 2, Ro 61-8048 row

Inhibition of human KMO activity: Absorbance at 340 nm after 1.5 h; activity normalized using sample, blank and control absorbances (equation 1); GraphPad Prism fit. Assay performed in duplicate. — Sections 2.1 and 2.4; equation 1; section 3.2; Figure 3C; Table 2, Ro 61-8048 row

Binding to immobilized recombinant human KMO

Biochemical assay · Recombinant human KMO immobilized on a CM5 SPR chip [1]

Ro 61-8048 showed concentration-dependent SPR responses with a reported equilibrium dissociation constant of 1.1 × 10−5 M. Binding affinity is distinct from the enzyme-inhibition IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding to recombinant human KMOKD 1.1 × 10−5 M[1]

Literature-Reported Treatment Conditions

Treatment concentration
Methods: 1.25–20 μM; Figure 6B labels: 1, 3, 10 and 20 μM
Exposure duration
60 s association and 60 s dissociation per cycle
Method
Surface plasmon resonance; 100 μL/min sample flow
Vehicle
HBS-P+ running buffer with 3% DMSO
Reported limits
Number of independent SPR runs and uncertainty of KD are not specified. Rounded figure labels differ from the stated lower end of the preparation range; these are retained as reported.
Methods and source locations

Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048

Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.

Sections 2.1, 2.6–2.7 and 3.4; Figure 5 caption; Figure 6B; Table 4, Ro 61-8048 row

Binding to recombinant human KMO: Biacore T200; reference flow cell with blank immobilization and DMSO solvent correction; binding parameters in Table 4. — Sections 2.1, 2.6–2.7 and 3.4; Figure 5 caption; Figure 6B; Table 4, Ro 61-8048 row

TPC-1 viability with SERINC2 knockdown and Ro 61-8048

Cell-based study · Human TPC-1 papillary thyroid carcinoma cells transfected with SERINC2 shRNA or vector control [2]

In the factorial vector/shRNA experiment, Ro 61-8048 at 20 nM reduced CCK-8 cell survival in SERINC2-knockdown cells relative to their DMSO condition. The vector-control comparison is marked nonsignificant. No exact bar heights are extracted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 cell survival with vector or SERINC2 shRNAQualitative response Lower survival with Ro 61-8048 in the shRNA condition; vector DMSO versus vector Ro 61-8048: ns[2]

Literature-Reported Treatment Conditions

Treatment concentration
20 nM
Exposure duration
Caption states drug treatment after 24 h shRNA transfection; subsequent drug exposure duration is not specified
Method
CCK-8 viability assay; shared method measures absorbance at 450 nm
Vehicle
DMSO; final fraction not specified
Co-treatment
SERINC2 shRNA; vector and DMSO conditions are shown. Alizarin is a separate comparator, not a stated co-treatment with Ro 61-8048.
Reported limits
Figure 6 caption reports mean ± SEM, whereas section 2.10 generally states mean ± SD of at least three experiments. Exact n and drug exposure time for panel F are not specified. No apoptosis-specific drug endpoint or formal synergy estimate is adopted.
Methods and source locations

Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048

Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.

Sections 2.3–2.5 and 2.10; section 3.4; Figure 6F and caption

CCK-8 cell survival with vector or SERINC2 shRNA: CCK-8 viability readout, Figure 6F; figure reports mean ± SEM and significance symbols; no exact n is attached to panel F. — Sections 2.3–2.5 and 2.10; section 3.4; Figure 6F and caption

Reversal of protection from 3-hydroxykynurenine injury

Cell-based study · Wild-type HEK293 versus HEK293 cells stably overexpressing human KMO(V5-6His) [3]

KMO-overexpressing cells were less susceptible to 500 μM 3-hydroxykynurenine (3HK). Co-treatment with 20 μM Ro61-8048 reversed this protection, with changes in mitochondrial membrane potential, LDH release and caspase-3/7 activity. This is a limiting, model-specific result rather than evidence that KMO inhibition is uniformly cytoprotective.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
3HK-associated mitochondrial dysfunction, LDH release and caspase-3/7 activityQualitative response Ro61-8048 abrogated the protection associated with KMO overexpression during 3HK challenge[3]

Literature-Reported Treatment Conditions

Treatment concentration
20 μM Ro61-8048
Exposure duration
24 h
Method
Parallel JC-1, LDH and caspase-3/7 assays under the same factorial challenge conditions
Co-treatment
500 μM 3HK; both cell types also have medium-only, Ro61-8048-only and 3HK-only controls
Reported limits
Ro61-8048 solvent/final vehicle concentration is not specified in the relevant assay methods. Methods describe triplicate treatment; caption gives n=6 per condition and three independent experiments. These statements are preserved without redefining n.
Methods and source locations

Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048

Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.

Results: KMO-overexpressing cells are protected from 3HK-mediated toxicity as a function of KMO activity; Figure 3a–c/caption; Methods: JC-1, LDH and caspase-3/7 assays

3HK-associated mitochondrial dysfunction, LDH release and caspase-3/7 activity: JC-1 red:green fluorescence ratio, supernatant LDH assay and caspase-3/7 luminescence; Figure 3a–c. Caption: n=6 per cell type/condition, SEM error bars; representative of three independent experiments. — Results: KMO-overexpressing cells are protected from 3HK-mediated toxicity as a function of KMO activity; Figure 3a–c/caption; Methods: JC-1, LDH and caspase-3/7 assays

Ro 61-8048 In Vivo Studies

In freely moving male rats, single intraperitoneal doses of Ro 61-8048 at 30 or 100 mg/kg were followed by increased extracellular kynurenic acid in the nucleus accumbens shell and ventral tegmental area relative to pre-injection baseline. With 100 mg/kg, KYNA peaked at 80 min in both regions (n=6 per group). This metabolite response does not establish brain penetration by the compound. [4]

Acute extracellular brain KYNA response in rats

Animal study · Freely moving male Sprague-Dawley rats; microdialysis in nucleus accumbens shell (NAc) and ventral tegmental area (VTA) [4]

After 30 or 100 mg/kg i.p. Ro 61-8048, extracellular KYNA increased relative to pre-injection baseline in both regions. At 100 mg/kg, the reported peak occurred at 80 min. These are brain metabolite responses, not direct measurements of brain drug penetration or disease efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Extracellular KYNA in NAc shell and VTATime-course response Increased relative to basal levels at both doses; 100 mg/kg peak at 80 min in both regions; n=6 per group; mean ± s.e.m.[4]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single injection
Treatment course
Acute microdialysis time course, up to 180 min after injection
Vehicle
5–6% Tween 80 in saline (shared Ro 61-8048 formulation)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ro 61-8048 30 mg/kgWithin-group pre-injection basal KYNA values; mean of three consecutive stable samples. Figure 1 does not show a separate vehicle-only curve.Extracellular KYNA increased relative to basal values; n=6 per group.[4]
Ro 61-8048 100 mg/kgWithin-group pre-injection basal KYNA values; mean of three consecutive stable samples. Figure 1 does not show a separate vehicle-only curve.Extracellular KYNA increased relative to basal values and peaked at 80 min in both regions; n=6 per group.[4]
Ro 61-8048 30 mg/kg
Model: Freely moving male Sprague-Dawley rats; nucleus accumbens shell and ventral tegmental area
Reported limits: Separate vehicle-only KYNA time course is not shown in Figure 1; precise analytical KYNA detection procedure is not detailed in the retrieved microdialysis paragraph.
Ro 61-8048 100 mg/kg
Model: Freely moving male Sprague-Dawley rats; nucleus accumbens shell and ventral tegmental area
Reported limits: Separate vehicle-only KYNA time course is not shown in Figure 1; precise analytical KYNA detection procedure is not detailed in the retrieved microdialysis paragraph.
Methods and source locations

Compound reported in the paper: Ro 61-8048; Compound label in the paper: Ro 61-8048

Results apply to the reported Ro 61-8048 material and experimental model; no salt conversion or validation of current Adooq lots is implied.

Results: Neurochemical effects of KMO inhibition in rats, first paragraph; Figure 1a–b/caption; Online Methods: Animals, Drugs, In-vivo microdialysis in freely-moving rats and Statistical analysis

Extracellular KYNA in NAc shell and VTA: In-vivo microdialysis; 20-min samples; percentage of basal values; post-hoc comparisons against basal values in Figure 1. — Results: Neurochemical effects of KMO inhibition in rats, first paragraph; Figure 1a–b/caption; Online Methods: Animals, Drugs, In-vivo microdialysis in freely-moving rats and Statistical analysis

Ro 61-8048 30 mg/kg · Results: Neurochemical effects of KMO inhibition in rats, first paragraph; Figure 1a–b/caption; Online Methods: Animals, Drugs, In-vivo microdialysis in freely-moving rats and Statistical analysis

Ro 61-8048 100 mg/kg · Results: Neurochemical effects of KMO inhibition in rats, first paragraph; Figure 1a–b/caption; Online Methods: Animals, Drugs, In-vivo microdialysis in freely-moving rats and Statistical analysis

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 199666-03-0
Applications Hydroxylase Inhibitor
Formula C17H15N3O6S2
Molecular Weight 421.45
SMILES
COC1=C(C=C(C=C1)S(=O)(=O)NC2=NC(=CS2)C3=CC(=CC=C3)[N+](=O)[O-])OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 80 mg/mL (189.82 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ro 61-8048 Research References

  1. [1] Puopolo T, Chang T, Liu C, et al. Gram-Scale Preparation of Cannflavin A from Hemp (Cannabis sativa L.) and Its Inhibitory Effect on Tryptophan Catabolism Enzyme Kynurenine-3-Monooxygenase Biology (2022). PMID: 36290320 DOI: 10.3390/biology11101416 Source material
  2. [2] Ying T, Wang X, Yao Y, et al. Integrative Methylome and Transcriptome Characterization Identifies SERINC2 as a Tumor-Driven Gene for Papillary Thyroid Carcinoma Cancers (2022). PMID: 36612238 DOI: 10.3390/cancers15010243 Source material
  3. [3] Wilson K, Auer M, Binnie M, et al. Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback Cell death & disease (2016). PMID: 27077813 DOI: 10.1038/cddis.2016.87 Source material
  4. [4] Justinova Z, Mascia P, Wu HQ, et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid Nature neuroscience (2013). PMID: 24121737 DOI: 10.1038/nn.3540 Source material

Publications

1 publication citing this product

  1. Tianxing Ying, .et al. , Cancers (Basel), 2022, Dec 30;15(1):243 PMID: 36612238

Added to your cart

View Cart Checkout
Loading...